|Articles|August 18, 2012

COMING SOON: Biosimilars: Overview of the FDA Draft Guidance Documents [Presentation]


Related to this article

Robert Z. Orlowski, MD, PhD | Image: MD Anderson Cancer Center
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Houston, Texas, oncologists and pharmacists from academic and community practices debated how teclistamab- and talquetamab-based regimens stack up against CAR T-cell therapy in second-line multiple myeloma, and what it will take—staffing, caregiver support, hospital partnerships, and payer buy-in—to move step-up dosing out of the hospital and into the clinic.